Home Clinical trials For patients Ovary NAPISTAR 1-01

NAPISTAR 1-01

A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

Open
Trial drug
TUB-040
Grade
High grade
Prior lines
1, 2, 3, 4, >4
Histology
Serous
Platin
Platinum resistant
Secondary platinum refractory
Phase
I

Treatment

The treatment option in this study is TUB-040.
TUB-040 is given intravenously every 3 weeks.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.